Novome develops Genetically Engineered Microbial Medicines (GEMMs), proprietary commensal bacterial strains designed to colonize the gut at controllable abundance and express therapeutic proteins. Its lead investigational product, NOV-001, is an oral combination of a recombinant live biotherapeutic and a botanically derived polysaccharide that demonstrated safe, dose-dependent colonization in a Phase 1 study. Novome is currently conducting a Phase 2a trial of NOV-001 in patients with enteric hyperoxaluria to evaluate safety, tolerability, and early efficacy. The company is also advancing multiple GEMM candidates for inflammatory bowel disease, including programs from a collaboration with Genentech, and exploring additional indications such as irritable bowel syndrome and immuno-oncology. Novome highlights platform capabilities to deliver high amounts of therapeutic proteins to the gastrointestinal tract via continuous, controlled secretion and to control strain abundance via once-daily prebiotic dosing. The recent financing will be used to advance the NOV-001 Phase 2a study and the broader GEMM pipeline. Novome Biotechnologies is a South San Francisco biotechnology company developing living medicines by engineering therapeutic bacteria to colonize the human gut. Its Genetically Engineered Microbial Medicines (GEMMs) platform supports a lead preclinical program in hyperoxaluria focused on a live biotherapeutic that degrades oxalate to prevent kidney stones. The company plans to use the financing to advance the hyperoxaluria program through Phase 1 clinical proof-of-concept and to expand the GEMMs platform into additional indications. Novome was founded in 2016 by scientists from Stanford University and the University of California, Berkeley based on research from Dr. Justin Sonnenburg's laboratory; founding scientists include Will DeLoache, Weston Whitaker, Zachary Russ, and Liz Shepherd. Leadership includes CEO Blake Wise and Co‑Founder/CSO Will DeLoache. The company is pursuing multiple additional programs that leverage its proprietary synthetic biology platform.

Total raised

$77M

Funding rounds

2

Latest round

Series B

Latest activity

Sep 2022